ArticleInflammopharmacology2026
Esculetin mitigates mast cell-mediated allergic inflammation and anaphylaxis by suppression FcεRI signaling.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esculetin Improves LPS/D-GalN Induced Acute Liver Injury Through AMPK/SIRT1/PGC-1α Signaling Pathway.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
OBJECTIVE AND
designMast cells are critical mediators in the initiation and propagation of allergic inflammation by secreting histamine and pro-inflammatory cytokines. Current treatments, including corticosteroids and antihistamines, provide symptomatic relief but do not directly target FcεRI-mediated mast cell activation. Esculetin, a natural bioactive compound from Fraxinus rhynchophylla Hance with potent antioxidative and anti-inflammatory effects, offers a promising but underexplored strategy for modulating allergic responses. This study investigates the pharmacological potential of esculetin in suppressing mast cell–mediated allergic inflammation. MATERIALS AND
methodsEsculetin was orally administered in immunoglobulin (Ig)E-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) mouse models. PCA and ASA responses were assessed by dye extravasation, ear swelling, hypothermia, and serum levels of IgE, IL-4, and histamine. In vitro studies using RBL-2H3 cells and bone marrow–derived mast cells examined FcεRI signaling and degranulation.
resultsEsculetin administered orally led to a dose-dependent inhibition of PCA responses, reflected by decreased Evans blue dye extravasation, reduced ear tissue swelling, and suppressed mast cell degranulation. In the ASA model, esculetin markedly alleviated hypothermia and significantly reduced serum levels of IgE, interleukin (IL)-4, and histamine. In vitro analyses using RBL-2H3 cells and murine bone marrow–derived mast cells showed that esculetin suppressed degranulation by attenuating FcεRI signaling cascades. Specifically, esculetin targeted Src family kinases such as Lyn and Fyn, as well as the downstream kinase Syk, ultimately reducing intracellular calcium influx.
conclusionThese findings suggest that esculetin may serve as a promising therapeutic candidate for mast cell-mediated allergic inflammatory disorders by inhibiting FcεRI signaling, thereby suppressing mast cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.